---
title: "Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030"
description: "Eli Lilly's stock has surged 580.36% since 2020, currently priced at .50, driven by strong financial performance and strategic developments. The company has potential for stock splits, and future reve"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/213861585.md"
published_at: "2024-09-09T17:19:54.000Z"
---

# Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

> Eli Lilly's stock has surged 580.36% since 2020, currently priced at .50, driven by strong financial performance and strategic developments. The company has potential for stock splits, and future revenue is projected to support its high valuation of 125 times earnings. Key growth drivers include an innovative drug pipeline with promising products like Mounjaro and Zepbound, alongside strategic acquisitions. Recent updates include executive appointments and partnerships aimed at enhancing drug developments and treatments for diabetes and Alzheimer’s disease. The outlook from 2025 to 2030 remains optimistic based on these developments.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 580.36% and currently trading at $899.50.  

The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years, Eli Lilly went from a $100 billion market capitalization to $740 billion today, which also makes it a potential stock split stock.

However, as investors, we care about the stock price years down the line and what Eli Lilly will do in the next 3 to 5 years and beyond.

That is why 24/7 Wall Street looks at projected revenue and net income to give you our best estimate of future stock prices from 2025 to 2030.

Other “experts” look at past growth rates and assign future stock prices to those past numbers. However, we will walk you through our assumptions and give you the key drivers we see propelling Eli Lilly’s stock in the future.

## Recent Eli Lilly Stock Updates and News

**9/9/2024**

Eli Lilly has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately, after a distinguished 23-year career with the company.

**9/6/2024**

Eli Lilly has partnered with the AI-driven drug discovery startup company, Genetic Leap. The partnership centers on developing new drugs, particularly those targeting RNA, which attempt to treat diseases at their genetic roots.

The deal is valued at $409 million, with Genetic Leap receiving upfront payments, milestone payments, and tiered royalties. The aim is to expedite the drug development process by leveraging Genetic Leap’s AI technology, which helps to identify and address challenging drug targets that are difficult to treat with conventional methods.

**9/5/2024**

Eli Lilly announced positive results from two phase 3 clinical trials (QWINT-1 and QWINT-3), which evaluated a new once-weekly insulin called efsitora alfa (efsitora) for adults with type 2 diabetes. These results suggest that efsitora could be a promising new treatment option for people with type 2 diabetes who need insulin. If approved, efsitora would offer the convenience of once-weekly dosing compared to the daily injections of traditional insulin.

**9/4/2024**

Eli Lilly has joined forces with QIAGEN to develop a test called QIAstat-Dx to detect APOE genotypes, which are related to Alzheimer’s disease. If this test is successful, it will be the first commercially available test for APOE genotyping.

**9/3/2024**

Novo Nordisk is experiencing a shortage of its diabetes drug, Ozempic, which is projected to persist into the fourth quarter. This is good news for Eli Lilly, which recently announced that supply constraints for Mounjaro and Zepbound have begun to ease.

## **Eli Lilly’s Recent Stock Success**

How did Eli Lilly’s stock price soar so much in the past few years? Let’s take a look at the numbers:

Share Price

Revenues\*

Net Income\*

2016

$80.36

$21.22

$2.74

2017

$77.55

$19.94

($0.21)

2018

$122.13

$21.49

$3.23

2019

$140.83

$22.32

$8.32

2020

$206.46

$24.54

$6.19

2021

$238.31

$28.32

$5.58

2022

329.07

$28.54

$6.25

2023

$745.91

$34.12

$5.24

\*Revenue and Net Income in Billions

Since 2016, Eli Lilly’s revenue grew by 60% but income grew by 91%. Typically you wouldn’t expect a company growing at its top line by 7% annually to see an 828% increase in share price, however, investor sentiment for the next line of drugs front ran the stock price.

For example, in 2016 Eli Lilly was trading 13 times the trailing 12 months earnings and the market has increased its valuation each year and currently trades at a 125 times earnings multiple.

This raises the valid question, is Eli Lilly overvalued or will future revenues make up for the expensive valuation?

## **3 Key Drivers of Eli Lilly Stock**

1.  **Innovated Drug Pipeline**: The current drug pipeline is loaded with several very high-potential drugs in development. Mounjaro, Zepbound, and Jardiance in the cardiometabolic category, Taltz in immunology, and Verzenio in oncology are the future of Eli Lilly’s growth. While the aforementioned are the safer bets, the company has a handful of other drugs that could hold blockbuster potential.
2.  **Strategic Acquisitions**: The acquisition of Morphic, with its promising drug candidate MORF-057, is a testament to Lilly’s strategic vision. This drug, if successful in late-stage trials, could become a major success in the treatment of inflammatory bowel disease (IBD). Lilly’s focus on acquiring mid-sized companies (13 since 2020) with promising pipelines has bolstered its own research and development efforts, positioning it well for future growth.
3.  **Operational Efficiency:** With a sound balance sheet, Eli Lilly should continue to improve operational efficiency and manage costs to have net income growth rates above revenue growth.

## **Eli Lilly (LLY) Stock Price Prediction in 2025**

The current Wall Street consensus 1-year price target of Eli Lilly stock is $898, which is -.07% than today’s price of $899.50. Of the 26 analysts covering Eli Lilly stock, the current rating is 1.71 or “Outperform” with 1-year price targets as high as $1,100 and as low as $540.00.

**24/7 Wall Street** sets its 1-year price target at $1,040. Taking a look at the sum of its parts, we see Eli Lilly’s vertices valued as follows:

Endocrinology

$735/ share

Oncology

$122/ Share

Cardiovascular

$4/ Share

Neuroscience

$16/ Share

Immunology

$38/ Share

Others and Pipeline

$110/ Share

Cash

$17/ Share

## **Eli Lilly’s Share Price Estimates 2025-2030**

Valuing Eli Lilly’s stock price for the coming years, we will take a look at expected revenue and net income and give our best estimate of the market value of the company by assigning a price-to-earnings multiple.

**Revenue**

**Net Income**

**EPS**

**2025**

$52.8

$17.29

19.11

**2026**

$62.5

$22.49

25.03

**2027**

$70.87

$27.12

30.39

**2028**

$80.68

$32.2

25.97

**2029**

$87.99

$36.45

40.58

**2030**

$96.67

$41.12

46.29

\*Revenue and net income reported in billions

## How Eli Lilly’s Next 5 Years Could Play Out

We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong revenue growth of 18.37% to $52.80 billion and net income expansion to $17.29 billion, continuing the upward trajectory from previous years.

For 2026, we anticipate a P/E ratio of 50 with an EPS of $25.03, leading to a price target of $1251.50. This reflects significant revenue growth of 18.37% to $62.50 billion and an increase in net income to $22.49 billion, driving higher earnings per share.

Heading into 2027, we project the P/E ratio to remain at 50, with EPS increasing to $30.39. This results in a price target of $1519.50. Continued revenue growth of 13.39% to $70.87 billion and net income expansion to $27.12 billion justifies this substantial increase in stock price.

With an EPS of $25.97 and a P/E ratio of 50 in 2028, we forecast the stock price to be $1298.50. A slight dip in EPS growth is expected, but sustained strong performance in net income to $32.20 billion and revenue growth of 13.84% to $80.68 billion keeps the stock highly valued.

By 2029, we estimate Eli Lilly’s EPS to rise to $40.58, with the P/E ratio adjusting to 40. This gives us a price target of $1623.20. The continuous revenue growth of 9.06% to $87.99 billion and net income expansion to $36.45 billion supports this higher valuation.

## Eli Lilly Stocks Price Target for 2030

**Price Target:** $1850.00  
**Upside:** 105.67%  
By 2030, we estimate Eli Lilly’s EPS to rise to $46.29, with the P/E ratio adjusting to 40. This gives us a price target of $1851.60. The continuous revenue growth of 9.86% to $96.67 billion and net income expansion to $41.12 billion supports this higher valuation.

Year

Price Target

% Change From Current Price

2025

$1140.00

Upside of 26.74%

2026

$1250.00

Upside of 38.97%

2027

$1520.00

Upside of 68.98%

2028

$1300.00

Upside of 44.52%

2029

$1623.00

Upside of 80.43%

2030

$180.00

Upside of 105.67%

## **Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)**

Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.

Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.

Click here now to get started.

The post Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 appeared first on 24/7 Wall St..

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元 | 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元。 | [Link](https://longbridge.com/en/news/274805260.md) |
| DELL, SPOT, UNH：全球最大的对冲基金正在市场中寻找抄底机会 | 桥水基金（Bridgewater Associates），全球最大的对冲基金，管理资产达 1360 亿美元，在 2025 年第四季度对表现不佳的股票进行了重大投资，包括戴尔（DELL）、Spotify（SPOT）和联合健康（UnitedHe | [Link](https://longbridge.com/en/news/276384705.md) |
| 沃尔玛四季度财报超预期但盈利指引不及预期，CEO 称 “美国低收入家庭只能勉强维持生计” | 沃尔玛 Q4 营收超预期，新财年盈利指引（每股 2.75-2.85 美元）远低于市场预期的 2.96 美元，显示通胀压力下消费者支出不确定性犹存，拖累股价下跌 1.38%。财报印证 K 型” 分化：高收入家庭驱动增长，低收入群体 “钱包吃紧 | [Link](https://longbridge.com/en/news/276398633.md) |
| 谷歌突然发布 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌发布了最新的大模型 Gemini 3.1 Pro，其推理性能较去年发布的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 评测中，Gemini 3.1 Pro 得分 77.1%，显示出强大的推理能力。新模型支持多源数据综合和复杂 | [Link](https://longbridge.com/en/news/276396515.md) |
| 最高法裁决后特朗普动用替补选择：加征 10% 全球关税 | 美国总统特朗普在最高法院裁决后宣布将加征 10% 的全球关税，以补救被推翻的关税措施。根据《1974 年贸易法》第 122 条款，现有的关税将全面生效。最高法院裁定特朗普政府的部分关税措施缺乏法律授权。市场风险提示，投资需谨慎。 | [Link](https://longbridge.com/en/news/276477629.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
